Response Evaluation Criteria in Solid Tumours (RECIST)
RECIST (Response Evaluation Criteria in Solid Tumours) is an evaluation of how malignancy responds to therapy. Objectively assessing the efficacy of cancer therapeutics is key to defining the best treatment options, as well as obtaining regulatory approval for novel cancer treatments in clinical trials. RECIST aims to provide a set of guidelines and rules to help radiologists avoid unconscious heterogeneity in evaluation or reporting style. It aims to provide a reproducible and reliable method for deciding and documenting whether malignancy is progressing, is responding, or is static allowing cancer clinicians to determine efficacy in relation to treatment decisions, or other end points for clinical trials, such as overall survival, progression free survival, or time to progression.
Learning Outcomes
- Explore the basic tenets and principles of RECIST 1.1
- Recognise and integrate RECIST 1.1 terminology in oncological care and reporting
- Investigate the different forms of response and how they relate to progression
- Use the practical examples to differentiate between marker/non-marker lesions and select the correct ones to use as a baseline
- Identify the process that leads up to creating a standard RECIST 1.1 report
Please note: To mark this course as complete on your Learning Dashboard and access your certificate of completion, you must finish all learning modules and submit the course evaluation.
-
Maguire Academy
At the Maguire Academy, we deliver communication and leadership training grounded in over 30 years of experience in healthcare, research, and real-world team dynamics. Our evidence-based courses are designed to create lasting change in practice. Through an experiential approach, we bring learning to life—ensuring deeper engagement, practical relevance, and maximum impact.
